RIPK1抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using RIPK1 mouse mAb against HL-60 (1), K562 (2), and Jurkat (3) cell lysate.    

  
  

Receptor-interacting protein kinase 1 (RIPK1) is a key regulator of cell survival, inflammation, and programmed cell death pathways, including apoptosis and necroptosis. As a serine/threonine kinase, RIPK1 interacts with death receptors (e.g., TNF receptor) and adaptor proteins to mediate downstream signaling. Depending on cellular context, it can promote NF-κB-mediated pro-survival signals or initiate death signaling complexes (e.g., necrosome). Dysregulation of RIPK1 is implicated in inflammatory diseases, neurodegenerative disorders, and cancer.

RIPK1 antibodies are essential tools for studying its expression, post-translational modifications (e.g., phosphorylation at Ser166), and interactions. They are widely used in techniques like Western blotting, immunoprecipitation, immunohistochemistry, and flow cytometry. Some antibodies target specific active forms (e.g., phosphorylated RIPK1) to assess kinase activity, while others detect total RIPK1 levels. Researchers often validate these antibodies using RIPK1-knockout cells or tissues to ensure specificity.

Therapeutic interest in RIPK1 has driven antibody development for preclinical studies, particularly in modulating inflammatory responses or cell death in conditions like Alzheimer’s disease, multiple sclerosis, and ischemic injury. Recent studies also explore RIPK1's role in immune cell regulation and its potential as a biomarker. However, interpreting results requires caution due to RIPK1's dual roles and context-dependent functions across cell types.